BioAtla (BCAB) Competitors $0.39 +0.01 (+2.63%) Closing price 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.78%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. ORMP, JMAC, IVVD, EXOZ, ELUT, CHRS, UNCY, XBIT, ZNTL, and SAVAShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Oramed Pharmaceuticals (ORMP), Maxpro Capital Acquisition (JMAC), Invivyd (IVVD), eXoZymes (EXOZ), Elutia (ELUT), Coherus Oncology (CHRS), Unicycive Therapeutics (UNCY), XBiotech (XBIT), Zentalis Pharmaceuticals (ZNTL), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Oramed Pharmaceuticals Maxpro Capital Acquisition Invivyd eXoZymes Elutia Coherus Oncology Unicycive Therapeutics XBiotech Zentalis Pharmaceuticals Cassava Sciences Oramed Pharmaceuticals (NASDAQ:ORMP) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Do analysts prefer ORMP or BCAB? BioAtla has a consensus target price of $5.00, suggesting a potential upside of 1,195.34%. Given BioAtla's stronger consensus rating and higher probable upside, analysts clearly believe BioAtla is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, ORMP or BCAB? Oramed Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Does the media refer more to ORMP or BCAB? In the previous week, BioAtla had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for BioAtla and 2 mentions for Oramed Pharmaceuticals. BioAtla's average media sentiment score of 0.55 beat Oramed Pharmaceuticals' score of 0.00 indicating that BioAtla is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAtla 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ORMP or BCAB more profitable? Oramed Pharmaceuticals' return on equity of -11.34% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Oramed PharmaceuticalsN/A -11.34% -10.73% BioAtla N/A -373.47%-116.55% Which has better earnings and valuation, ORMP or BCAB? Oramed Pharmaceuticals has higher earnings, but lower revenue than BioAtla. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOramed Pharmaceuticals$1.34M65.85-$19.06M-$0.44-4.91BioAtla$11M2.05-$69.78M-$1.22-0.32 Do institutionals and insiders have more ownership in ORMP or BCAB? 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 13.7% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 11.5% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryBioAtla beats Oramed Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.97M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-0.3220.3027.1920.03Price / Sales2.05251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book1.547.397.925.55Net Income-$69.78M-$55.04M$3.17B$248.49M7 Day Performance-2.53%3.01%2.18%5.37%1 Month Performance-19.90%-0.21%1.25%6.63%1 Year Performance-70.76%4.48%33.90%21.20% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.715 of 5 stars$0.39+2.6%$5.00+1,195.3%-71.2%$21.97M$11M-0.3260ORMPOramed Pharmaceuticals0.2575 of 5 stars$2.25+4.7%N/A-14.7%$87.83M$1.34M-5.1110JMACMaxpro Capital AcquisitionN/A$6.51+1.5%N/A+3,111.3%$87.42MN/A0.002,021Gap DownIVVDInvivyd3.4235 of 5 stars$0.72-1.6%$5.85+718.2%-34.5%$87.15M$25.38M-0.60100EXOZeXoZymesN/A$9.88-4.9%N/AN/A$86.94MN/A0.0029Gap DownHigh Trading VolumeELUTElutia3.5635 of 5 stars$1.98-5.7%$8.00+304.0%-53.9%$86.34M$24.38M-1.03180Positive NewsCHRSCoherus Oncology3.6967 of 5 stars$0.73-1.6%$4.68+540.4%-39.8%$86.15M$266.96M-0.65330Gap DownUNCYUnicycive Therapeutics3.1135 of 5 stars$4.77-29.9%$60.00+1,157.9%+1.4%$85.96M$680K-0.949High Trading VolumeXBITXBiotech0.4552 of 5 stars$2.97+6.1%N/A-44.5%$85.37M$4.01M-2.30100Positive NewsGap UpZNTLZentalis Pharmaceuticals1.5247 of 5 stars$1.16-1.7%$8.37+621.3%-65.5%$84.90M$67.43M-0.37160SAVACassava Sciences3.8766 of 5 stars$1.81+3.4%$54.50+2,911.0%-80.3%$84.54MN/A-1.2130 Related Companies and Tools Related Companies ORMP Alternatives JMAC Alternatives IVVD Alternatives EXOZ Alternatives ELUT Alternatives CHRS Alternatives UNCY Alternatives XBIT Alternatives ZNTL Alternatives SAVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAB Stock Alerts